Components:
Medically reviewed by Fedorchenko Olga Valeryevna, PharmD. Last updated on 15.05.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Carefully consider the potential benefits and risks of Bonmin, EC-Bonmin, ANAPROX, ANAPROX DS or Bonmin Suspension and other treatment options before deciding to use Bonmin, EC-Bonmin, ANAPROX, ANAPROX DS or Bonmin Suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
Bonmin as Bonmin, EC-Bonmin, ANAPROX, ANAPROX DS or Bonmin Suspension is indicated:
- For the relief of the signs and symptoms of rheumatoid arthritis
- For the relief of the signs and symptoms of osteoarthritis
- For the relief of the signs and symptoms of ankylosing spondylitis
- For the relief of the signs and symptoms of juvenile arthritis
Bonmin as Bonmin Suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient's weight.
Bonmin as Bonmin, ANAPROX, ANAPROX DS and Bonmin Suspension is also indicated:
- For relief of the signs and symptoms of tendonitis
- For relief of the signs and symptoms of bursitis
- For relief of the signs and symptoms of acute gout
- For the management of pain
- For the management of primary dysmenorrhea
EC-Bonmin is not recommended for initial treatment of acute pain because the absorption of Bonmin is delayed compared to absorption from other Bonmin-containing products.
Bonmin is a nonsteroidal anti-inflammatory drug (NSAID). Bonmin works by reducing hormones that cause inflammation and pain in the body.
Bonmin is used to treat pain or inflammation caused by conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps.
The delayed-release or extended-release tablets are slower-acting forms of Bonmin that are used only for treating chronic conditions such as arthritis or ankylosing spondylitis. These forms of Bonmin will not work fast enough to treat acute pain.
Bonmin may also be used for purposes not listed in this medication guide.
Usual Adult Dose for Ankylosing Spondylitis:
Initial: 250 mg to 500 mg (Bonmin) or 275 mg to 550 mg (Bonmin) orally twice a day. The initial dose for Bonmin controlled-release is two 375 mg tablets (750 mg) orally once a day, one 750 mg tablet orally once a day, or two 500 mg tablets (1000 mg) orally once a day.
Maintenance: May be increased to a daily maximum of 1500 mg (Bonmin) or 1650 mg (Bonmin) in 2 divided doses, for limited periods up to 6 months. In patients who tolerate lower doses well, the dose of Bonmin controlled-release may be increased to two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) orally once a day for limited periods.
Usual Adult Dose for Osteoarthritis:
Initial: 250 mg to 500 mg (Bonmin) or 275 mg to 550 mg (Bonmin) orally twice a day. The initial dose for Bonmin controlled-release is two 375 mg tablets (750 mg) orally once a day, one 750 mg tablet orally once a day, or two 500 mg tablets (1000 mg) orally once a day.
Maintenance: May be increased to a daily maximum of 1500 mg (Bonmin) or 1650 mg (Bonmin) in 2 divided doses, for limited periods up to 6 months. In patients who tolerate lower doses well, the dose of Bonmin controlled-release may be increased to two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) orally once a day for limited periods.
Usual Adult Dose for Rheumatoid Arthritis:
Initial: 250 mg to 500 mg (Bonmin) or 275 mg to 550 mg (Bonmin) orally twice a day. The initial dose for Bonmin controlled-release is two 375 mg tablets (750 mg) orally once a day, one 750 mg tablet orally once a day, or two 500 mg tablets (1000 mg) orally once a day.
Maintenance: May be increased to a daily maximum of 1500 mg (Bonmin) or 1650 mg (Bonmin) in 2 divided doses, for limited periods up to 6 months. In patients who tolerate lower doses well, the dose of Bonmin controlled-release may be increased to two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) orally once a day for limited periods.
Usual Adult Dose for Acute Gout:
750 mg (Bonmin) or 825 mg (Bonmin) orally one time, followed by 250 mg (Bonmin) or 275 mg (Bonmin) every 8 hours until the gouty attack has resolved, usually 2 to 3 days. The recommended dose of Bonmin controlled-release is two to three 500 mg tablets (1000 to 1500 mg) orally on the first day, followed by two 500 mg tablets (1000 mg) orally daily until the attack has subsided.
Usual Adult Dose for Bursitis:
550 mg Bonmin orally once, followed by 550 mg Bonmin every 12 hours, or 275 mg (Bonmin)/250 mg (Bonmin) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg Bonmin or 1000 mg Bonmin. The recommended initial dose of Bonmin controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Adult Dose for Tendonitis:
550 mg Bonmin orally once, followed by 550 mg Bonmin every 12 hours, or 275 mg (Bonmin)/250 mg (Bonmin) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg Bonmin or 1000 mg Bonmin. The recommended initial dose of Bonmin controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Adult Dose for Dysmenorrhea:
550 mg Bonmin orally once, followed by 550 mg Bonmin every 12 hours, or 275 mg (Bonmin)/250 mg (Bonmin) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg Bonmin or 1000 mg Bonmin.
Over-the-counter preparation: Bonmin 220 mg orally every 8 hours as needed. Do not exceed 2 caplets in any 8- to 12-hour period.
The recommended initial dose of Bonmin controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Adult Dose for Pain:
550 mg Bonmin orally once, followed by 550 mg Bonmin every 12 hours, or 275 mg (Bonmin)/250 mg (Bonmin) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg Bonmin or 1000 mg Bonmin.
Over-the-counter preparation: Bonmin 220 mg orally every 8 hours as needed. Do not exceed 2 caplets in any 8- to 12-hour period.
The recommended initial dose of Bonmin controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Geriatric Dose for Pain:
Over-the-counter preparation - 220 mg (Bonmin) orally every 12 hours or 250 mg (Bonmin) orally every 8 hours as needed.
Usual Pediatric Dose for Fever:
Dosage guidelines are based on Bonmin:
Greater than 2 years: 2.5 to 10 mg/kg/dose. Maximum daily dose is 10 mg/kg, given every 8 to 12 hours.
Usual Pediatric Dose for Pain:
Dosage guidelines are based on Bonmin:
Greater than 2 years: 2.5 to 10 mg/kg/dose. Maximum daily dose is 10 mg/kg, given every 8 to 12 hours.
Usual Pediatric Dose for Juvenile Rheumatoid Arthritis:
Dosage guidelines are based on Bonmin:
Greater than or equal to 2 years: 5 mg/kg orally twice a day. Maximum dose: 1000 mg/day.
See also:
What is the most important information I should know about Bonmin?
Bonmin, EC-Bonmin, ANAPROX, ANAPROX DS and Bonmin Suspension are contraindicated in patients with known hypersensitivity to Bonmin and Bonmin.
Bonmin, EC-Bonmin, ANAPROX, ANAPROX DS and Bonmin Suspension should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.
Bonmin, EC-Bonmin, ANAPROX, ANAPROX DS and Bonmin Suspension are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Use Bonmin sustained-release tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Bonmin sustained-release tablets comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Bonmin sustained-release tablets refilled.
- Swallow Bonmin sustained-release tablets whole. Do not break, crush, or chew before swallowing.
- Take Bonmin sustained-release tablets by mouth. It may be taken with food if it upsets your stomach. Taking it with food may not lower the risk of stomach or bowel problems (eg, bleeding, ulcers). Talk with your doctor or pharmacist if you have persistent stomach upset.
- Take Bonmin sustained-release tablets with a full glass of water (8 oz [240 mL]) as directed by your doctor.
- If you take antacids, cholestyramine, or sucralfate, ask your doctor or pharmacist how to take them with Bonmin sustained-release tablets.
- If you miss a dose of Bonmin sustained-release tablets and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose. Go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Bonmin sustained-release tablets.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Bonmin is used to relieve mild to moderate pain from various conditions. It also reduces pain, swelling, and joint stiffness from arthritis. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID). It works by blocking your body's production of certain natural substances that cause inflammation.
If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section.
This form of Bonmin is absorbed slowly and should not be used for pain that needs quick relief (such as during a gout attack). Ask your doctor or pharmacist about using a different form of this drug or other medications for quick relief of pain.
How to use EC-Bonmin
Read the Medication Guide provided by your pharmacist before you start using Bonmin and each time you get a refill. If you have any questions, ask your doctor or pharmacist.
Take this medication by mouth as directed by your doctor, usually twice daily with or without food. Swallow this medication whole. Do not break, crush, or chew the tablets. Doing so can release the drug too quickly, increasing the risk of side effects. Take this medication with a full glass of water (8 ounces/240 milliliters) unless your doctor directs you otherwise. Do not lie down for at least 10 minutes after taking this drug.
The dosage is based on your medical condition and response to treatment. To reduce your risk of stomach bleeding and other side effects, take this medication at the lowest effective dose for the shortest possible time. Do not increase your dose or take this drug more often than directed. For ongoing conditions such as arthritis, continue taking this medication as directed by your doctor.
For certain conditions (such as arthritis), it may take up to two weeks of taking this drug regularly until you get the full benefit.
Tell your doctor if your condition does not improve or if it worsens.
See also:
What other drugs will affect Bonmin?
The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.
In vitro studies have shown that Bonmin anion, because of its affinity for protein, may displace from their binding sites other drugs which are also albumin-bound.
Theoretically, the Bonmin anion itself could likewise be displaced. Short-term controlled studies failed to show that taking the drug significantly affects prothrombin times when administered to individuals on coumarin-type anticoagulants. Caution is advised nonetheless, since interactions have been seen with other nonsteroidal agents of this class. Similarly, patients receiving the drug and a hydantoin, sulfonamide or sulfonylurea should be observed for signs of toxicity to these drugs.
Concomitant administration of Bonmin and aspirin is not recommended because Bonmin is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
The natriuretic effect of furosemide has been reported to be inhibited by some drugs of this class. Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported. Bonmin and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
Probenecid given concurrently increases Bonmin anion plasma levels and extends its plasma half-life significantly.
Caution should be used if Bonmin is administered concomitantly with methotrexate. Bonmin, Bonmin and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
Drug/Laboratory Test Interactions
Bonmin may decrease platelet aggregation and prolong bleeding time. This effect should be kept in mind when bleeding times are determined. The administration of Bonmin may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-dinitrobenzene used in this assay. Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with Bonmin be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used.
Bonmin may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA).
See also:
What are the possible side effects of Bonmin?
Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis or osteoarthritis are listed below. In general, reactions in patients treated chronically were reported 2 to 10 times more frequently than they were in short-term studies in the 962 patients treated for mild to moderate pain or for dysmenorrhea. The most frequent complaints reported related to the gastrointestinal tract.
A clinical study found gastrointestinal reactions to be more frequent and more severe in rheumatoid arthritis patients taking daily doses of 1500 mg Bonmin compared to those taking 750 mg Bonmin.
In controlled clinical trials with about 80 pediatric patients and in well-monitored, open-label studies with about 400 pediatric patients with juvenile arthritis treated with Bonmin, the incidence of rash and prolonged bleeding times were increased, the incidence of gastrointestinal and central nervous system reactions were about the same, and the incidence of other reactions were lower in pediatric patients than in adults.
In patients taking Bonmin in clinical trials, the most frequently reported adverse experiences in approximately 1% to 10% of patients are:
Gastrointestinal (GI) Experiences, including: heartburn*, abdominal pain*, nausea*, constipation*, diarrhea, dyspepsia, stomatitis
Central Nervous System: headache*, dizziness*, drowsiness*, lightheadedness, vertigo
Dermatologic: pruritus (itching)*, skin eruptions*, ecchymoses*, sweating, purpura
Special Senses: tinnitus*, visual disturbances, hearing disturbances
Cardiovascular: edema*, palpitations
General: dyspnea*, thirst
*Incidence of reported reaction between 3% and 9%. Those reactions occurring in less than 3% of the patients are unmarked.
In patients taking NSAIDs, the following adverse experiences have also been reported in approximately 1% to 10% of patients.
Gastrointestinal (GI) Experiences, including: flatulence, gross bleeding/perforation, GI ulcers (gastric/duodenal), vomiting
General: abnormal renal function, anemia, elevated liver enzymes, increased bleeding time, rashes
The following are additional adverse experiences reported in <1% of patients taking Bonmin during clinical trials and through postmarketing reports. Those adverse reactions observed through postmarketing reports are italicized.
Body as a Whole: anaphylactoid reactions, angioneurotic edema, menstrual disorders, pyrexia (chills and fever)
Cardiovascular: congestive heart failure, vasculitis, hypertension, pulmonary edema
Gastrointestinal: inflammation, bleeding (sometimes fatal, particularly in the elderly), ulceration, perforation and obstruction of the upper and lower gatrointestinal tract. Esophagitis, stomatitis, hematemesis, pancreatitis, vomiting, colitis, exacerbation of inflammatory bowel disease (ulcerative colitis, Crohn’s disease)
Hepatobiliary: jaundice, abnormal liver function tests, hepatitis (some causes have been fatal)
Hemic and Lymphatic: eosinophilia, leucopenia, melena, thrombocytopenia, agranulocytosis, granulocytopenia, hemolytic anemia, aplastic anemia
Metabolic and Nutritional: hyperglycemia, hypoglycemia
Nervous System: inability to concentrate, depression, dream abnormalities, insomnia, malaise, myalgia, muscle weakness, aseptic meningitis, cognitive dysfunction, convulsions
Respiratory: eosinophilic pneumonitis, asthma
Dermatologic: alopecia, urticaria, skin rashes, toxic epidermal necrolysis, erythema multiforme, erythema nodosum, fixed drug eruption, lichen planus, pustular reaction, systemic lupus erythematoses, Stevens-Johnson syndrome, photosensitive dermatitis, photosensitivity reactions, including rare cases resembling porphyria cutanea tarda (pseudoporphyria) or epidermolysis bullosa. If skin fragility, blistering or other symptoms suggestive of pseudoporphyria occur, treatment should be discontinued and the patient monitored.
Special Senses: hearing impairment, corneal opacity, papillitis, retrobulbar optic neuritis, papilledema
Urogenital: glomerular nephritis, hematuria, hyperkalemia, interstitial nephritis, nephrotic syndrome, renal disease, renal failure, renal papillary necrosis, raised serum creatinine
Reproduction (Female): infertility
In patients taking NSAIDs, the following adverse experiences have also been reported in <1% of patients.
Body as a Whole: fever, infection, sepsis, anaphylactic reactions, appetite changes, death
Cardiovascular: hypertension, tachycardia, syncope, arrhythmia, hypotension, myocardial infarction
Gastrointestinal: dry mouth, esophagitis, gastric/peptic ulcers, gastritis, glossitis, eructation
Hepatobiliary: hepatitis, liver failure
Hemic and Lymphatic: rectal bleeding, lymphadenopathy, pancytopenia
Metabolic and Nutritional: weight changes
Nervous System: anxiety, asthenia, confusion, nervousness, paresthesia, somnolence, tremors, convulsions, coma, hallucinations
Respiratory: asthma, respiratory depression, pneumonia
Dermatologic: exfoliative dermatitis
Special Senses: blurred vision, conjunctivitis
Urogenital: cystitis, dysuria, oliguria/polyuria, proteinuri
Each tablet contains Naproxen 200 mg and sodium 20 mg. It also contains the following inactive ingredients: Povidone, microcrystalline cellulose, talc, magnesium stearate, purified water and Opadry (blue) in the coating. It is lactose- and gluten-free.
The sodium content of Bonmin is low, similar to a slice of wheat bread.